What are the blood products?

Question 1: What kinds of blood products are there? Blood and blood products are the result of people helping each other in medicine, just like people enjoying resources on the Internet.

Blood (whole blood) can save the lives of many patients who have lost blood. I was born thanks to a blood donor.

Plasma can replenish water for patients with hypertonic dehydration, and it is difficult to synthesize it artificially.

Platelets can help hemophiliacs.

It can be said that blood and blood products are the necessities of human beings in modern medical care, the symbol of the moral development of human society, the expression of people's spirit of mutual assistance and the most personalized social care.

If you have graduated from high school and are in good health, I hope you can donate blood!

If my answer is useful to you, I sincerely hope to be chosen as the best by you. I am a novice who needs 20 points of encouragement! thank you

Question 2: As a branch of biomedicine, medical blood products include what blood products? The future prospect must also be in modern biotechnology, and the expansion and integration of industries is an inevitable trend.

There are several categories, namely vaccines, vaccine antibodies and antigen biological diagnostic reagents.

Question 3: How many blood products are there in China? There are 34 blood products manufacturers in China, of which more than 20 are in normal operation, and only more than 100 tons of plasma are processed annually. Starting from 1998, the state requires all blood products enterprises to adopt mechanized mining, which increases the cost per ton of albumin by nearly 10 million yuan. Coupled with the domestic economic downturn in the past two or three years, the demand for related products is insufficient, and it is more difficult for enterprises to sell their products. The ex-factory price of most enterprises' products is lower than the price stipulated by the state, and the profit rate of products has declined. The key to the survival of such enterprises lies in adopting new technologies to reduce costs and separating more drug proteins from plasma through technological innovation to increase profits. In terms of production technology, domestic human albumin and human immunoglobulin products all adopt low-temperature ethanol method; More than 20% of the production units use filter pressing instead of centrifugation for liquid-solid separation, which greatly improves the output of products (mainly human albumin) and changes the production process from the open operation of centrifugal separation to the closed operation of filter pressing. In order to improve the safety of blood products, one-step or two-step cleaning/inactivation process has been added to all blood products in China as required. In terms of product quality, the quality of human albumin produced in China has reached the level of similar products in the world; The IgG subclass and Fc of human immunoglobulin for intravenous injection are fully functional, and some quality indexes of immunoglobulin (product purity, monomer and dimer content, hepatitis B antibody content) are higher than the European Pharmacopoeia standards. Compared with the European Pharmacopoeia, the quality of freeze-dried human coagulation factor VIII concentrated preparation and freeze-dried human thrombin complex still lags behind. Compared with foreign blood products enterprises, the main problems in domestic blood products industry are: there are many production enterprises, but the production scale is small; Insufficient comprehensive utilization of blood; There are still gaps in blood source management and strengthening the safety of blood products. China's blood products industry is in a serious state of short supply. The theoretical demand for plasma in China is 8000 tons, while the total amount of plasma collected in China in 2065,438+02 is only about 4000 tons. The imbalance between supply and demand has led to a strong seller pattern in the blood products industry and created a high degree of prosperity in the industry. According to the analysis of Forecast and Analysis of Production and Marketing Demand and Investment of Blood Products Industry in China, there is a very simple rule in the blood products industry-the richer the product line, the higher the profit rate. Because the raw materials for producing blood products are all the same batch of plasma, if more products can be extracted from the same batch of plasma, the cost can be effectively shared. The generally accepted model in the industry is that albumin, static propyl alcohol and coagulation factor VIII are the main products to ensure basic profits, and then other products (mainly special immunity, coagulation factor VII, fibrinogen, α- 1 antitrypsin, PCC) create additional profits. This requires enterprises to have advanced technology, which can effectively separate as many kinds of protein as possible from the same batch of plasma. In recent years, with the sharp increase in nutrition expenses of pulp collectors and the rising cost of testing and transportation, the blood products industry is facing the risk of rising comprehensive cost and falling gross profit margin of products. Although this effect can be eliminated by raising prices in the short term, there is a great risk of price reduction because blood products basically enter the national medical insurance. Therefore, increasing technical input, improving blood utilization rate and optimizing product structure are the primary tasks for future development. With the continuous improvement of domestic medical level, the awareness of clinical application of blood products and the continuous improvement of domestic medical security level, the proportion of albumin in the consumption structure of blood products in China will continue to decline, the proportion of static acrylic acid and specific immunoglobulin will continue to increase, and the consumption structure of blood products will continue to be optimized.

Question 4: What are erythrocyte and platelet albumin in blood products?

Generally speaking, formal channels are safe.

But if some blood donors get some diseases,

In a certain window period, the blood station can't detect it.

So blood transfusion products are risky.

Question 5: What are the blood products concept stocks Hualan Bio 002007?

Research institution: Southwest Securities.

It is estimated that the pulp output will exceed 1000 tons in 20 17 years, consolidating the leading position in the industry. 1) Company has 17 pulp stations, the number of which is second only to Shanghai Laishi (002252) and Tiantan Bio (600 16 1). It is estimated that the pulp collection capacity in 20 15 will be 700 tons, second only to Shanghai Laishi. After Shizhu Sub-station obtained the pulp mining license, all the six sub-stations in Chongqing have been able to start formal pulp mining, and it is expected that the pulp mining capacity of Chongqing Pulp Station will increase by more than 30%. With the tapping of the potential of existing pulp stations, it is estimated that the pulp output will exceed 1000 tons in 20 17 years. 2) From the product line, the company has 1 1 varieties such as human albumin, intravenous human immunoglobulin, coagulation factor VIII, tetanus human immunoglobulin, human fibrinogen, etc. It is one of the largest companies in China at present, and its overall profitability is at the upstream of the industry.

Will enjoy the opportunity of rising volume and price in the blood products industry. Since the cancellation of the highest retail price in June, 2065438+2005, the dividend of blood products industry chain has been released, and the enthusiasm of pulp station expansion has been continuously improved. 1) According to the setting of pulp stations, there were about 40 new pulp batch stations in China in 20 14 and 20 15. Recently, the approval of Chongqing and Guangdong has been accelerated, indicating that the approval attitude of pulp stations in some provinces has changed positively. At present, the company has exclusive access to the resources of pulp stations in Chongqing and Henan, and has a strong ability to apply for approval from pulp stations in the two places. Only nine counties in Chongqing have no pulp stations, and Henan, as a populous province, has greater development potential. 2) From the point of view of product price, other products except albumin have a strong expectation of price increase, and can be imported from abroad at a lower price before the demand is effectively alleviated. The ex-factory price of static propylene has maintained a steady and rising trend, and it is expected to maintain the annual price increase of 10%-20% in the future. The price elasticity of small varieties such as special exemption and human fibrinogen is greater. We believe that the blood products industry has ushered in a boom cycle of rising volume and price. As an industry leader, the company has a huge room for performance improvement.

WHO pre-certification is expected to promote the vaccine volume and lay out the blue ocean market of monoclonal antibodies in advance. The influenza vaccine has been certified by WHO, and the meningococcal vaccine will be certified by WHO soon. It is estimated that it will enter the WHO vaccine procurement system with a scale of more than US$ 654.38 billion, and based on the international market, export will become a new growth point of vaccine business. Hualan Genetic Engineering Co., Ltd., a joint venture subsidiary, is mainly engaged in monoclonal antibody business. The annual sales of adam, rituximab, Beva and trastuzumab in 20 14 all exceeded $6 billion. Domestic generic drugs are currently in the clinical stage, and are expected to become hundreds of millions of large varieties after listing, with a large market space in the future.

Profit forecast and investment advice. It is estimated that the EPS of the company in 20 15-20 17 years will be 1.08 yuan, 1.30 yuan, 1.6 1 yuan respectively, corresponding to the current P/E ratio of 39 times, 33 times and 26 times. We believe that the company is a first-line enterprise of blood products with strong endogenous growth momentum, and will fully share the dividend of the industry boom cycle and give a "buy" rating.

Boya biology 300294

Research institution: Southwest Securities.

The performance exceeded expectations, and the price increase of blood products was the core reason. We had previously predicted that the company's net profit for 20 15 was 134 billion yuan (+29%). The main reason why this performance forecast exceeded our expectations is that the rise in the price of blood products has made a great contribution to the performance. Since the National Development and Reform Commission (NDRC) cancelled the maximum retail price limit from 2065438 to June 2005, blood products companies have raised prices one after another. At present, the price increase of static C is close to 20%, and that of glass fiber is over 100%. The price increase and performance exceeded market expectations. Long-term shortage of supply is the main driving force for the price increase of blood products. At present, China's annual demand for plasma exceeds 8,000 tons, but the annual collection of plasma is only about 6,000 tons, which is far from meeting the market demand. In terms of products, albumin can import products with lower prices from abroad, so there is basically no room for price increase; Coagulation factor VIII is mainly paid by medical insurance, and there is not much room for price increase; The use of static propylene involves a large number of people, so it is impossible to raise the price significantly; Fibrinogen is a disposable drug, which accounts for a small proportion and is mainly paid by patients, so there is the biggest room for price increase. The company has a small market share, mainly following the industry and gradually raising prices; However, the market share of glass fiber exceeds 40%, with high technical barriers and strong market pricing ability, and there is still huge room for price increase in the future. With the gradual increase in the price of blood products, the company's income and profits will increase substantially, which will promote the rapid growth of performance.

The capacity of the pulp station is strong, and the pulp output has achieved leap-forward growth. In 20 14, only five pulp stations were put into production, and the pulp collection capacity was only about 130 tons, but by 20 15, the company had ...

Question 6: Who are the listed companies of blood products? The blood products of Chengdu Rong Sheng Pharmaceutical Co., Ltd. account for almost half of the profits of Tiantan Company.

In turn, Hualan Bio, Shanghai Laishi, Tiantan Bio.

At present, the source of plasma in Hualan is limited, while the price of blood products is rising.

Question 7: What are the blood products? What kind of enterprise can produce? Regulations on the Administration of Blood Products Chapter I General Provisions Article 1 In order to strengthen the administration of blood products, prevent and control blood-borne diseases and ensure the quality of blood products, these regulations are formulated in accordance with the Drug Administration Law and the Law on the Prevention and Control of Infectious Diseases. Article 2 These Regulations shall apply to the collection and supply of raw plasma and the production and marketing of blood products in People's Republic of China (PRC). Article 3 The administrative department of health of the State Council shall supervise and manage the collection and supply of raw plasma and the production and marketing of blood products throughout the country. The local people's health administrative departments at or above the county level shall, in accordance with the duties stipulated in Article 30 of these regulations, supervise and manage the collection and supply of raw plasma and the production and operation of blood products within their respective administrative areas. Chapter II Management of Raw Plasma Article 4 The State implements a unified planning and setting system for plasma collection stations. The administrative department of public health of the State Council shall, according to the production demand of raw plasma approved by the state, make an overall plan for the layout, quantity and scale of apheresis plasma stations. The people's health administrative departments of provinces, autonomous regions and municipalities directly under the Central Government shall, according to the overall planning, formulate the planning for the construction of plasma collection stations and the regional planning for plasma collection within their respective administrative areas, and report them to the health administrative department of the State Council for the record. Article 5 A plasma collection station shall be established by a blood product production unit or the health administrative department of the people's government at the county level, which is specialized in plasma collection activities and has the qualification of an independent legal person. No other unit or individual may collect plasma from the activity list. Article 6 The establishment of plasma collection stations must meet the following conditions: (1) Conforming to the planning of the layout, quantity and scale of plasma collection stations; (2) Having health professionals suitable for the collected raw plasma; (3) Having a place and sanitary environment suitable for collecting raw plasma; (4) Having an identification system to identify the plasma donors; (5) Having plasma collection machinery and other facilities suitable for the collected raw plasma; (6) Having technicians and necessary instruments and equipment for quality inspection of the collected raw plasma. Article 7 The application for setting up apheresis plasma stations shall be first examined by the health administrative department of the people's government at the county level, and then examined and approved by the health administrative department of the people's government of a city or autonomous prefecture divided into districts or the health administrative department of an agency established by the people's government of a province or autonomous region. And report to the health administrative department of the people's government of the province, autonomous region or municipality directly under the Central Government for examination and approval; Upon examination, if it meets the requirements, the health administrative department of the people's government of the province, autonomous region or municipality directly under the Central Government shall issue the plasma collection permit and report it to the health administrative department of the State Council for the record. Plasma collection stations can only screen plasma donors and collect plasma in areas designated by the health administrative departments of provinces, autonomous regions and municipalities directly under the Central Government. Article 8 The license for collecting simplex shall specify the period of validity. Ninth in a plasma collection area, only one plasma collection station can be set up. It is strictly forbidden to collect plasma from plasma donors and other personnel in non-designated areas. Tenth plasmapheresis stations must carry out health examination for plasmapheresis; If it passes the inspection, the health administrative department of the people at the county level shall issue a plasma supply certificate. Health examination standards for blood donors shall be formulated by the health administrative department of the State Council. Article 11 The health administrative departments of provinces, autonomous regions and municipalities directly under the Central Government shall be responsible for the design and printing of the Certificate of Plasma Donation. "Plasmapheresis Certificate" shall not be altered, forged or transferred. Twelfth before collecting plasma, the identity of the plasma donor must be identified, and the plasma donor certificate must be verified, and the health examination and blood test should be carried out in accordance with the prescribed procedures; For those who pass the inspection, collect plasma according to relevant technical operation standards and procedures, and establish health examination for plasma donors and record files for plasma donors; If the inspection and detection are unqualified, the plasma supply certificate shall be recovered by the plasma collection station and destroyed under the supervision of the local people's health administrative department at the county level. It is forbidden to collect plasma without plasma supply certificate. The operating standards and procedures of plasma apheresis technology shall be formulated by the health administrative department of the State Council. Thirteenth plasma collection stations can only supply raw plasma to a blood product production unit that has signed a quality responsibility letter with them, and it is strictly forbidden to supply raw plasma to any other unit. Fourteenth apheresis plasma stations must use apheresis plasma. & gt

Question 8: What are the main blood component products? The types of blood products include: (1) whole blood: ① new blood; ② Blood stored in the bank; ⑵ Blood composition: ① Plasma (fresh plasma, frozen plasma, preserved plasma); ② Red blood cells (concentrated red blood cells, washed red blood cells and red blood cell suspension);

③ concentrated suspension of leukocytes; ④ Platelet concentrated suspension; ⑤ Various coagulants, such as prothrombin complex; (3) Other blood products: ① albumin solution; ② Fibrinogen; ③ Anti-hemophilic globulin concentrate.